MUMBAI, India and NAPLES, Fla., July 31, 2026
Lupin Limited has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Sugammadex Injection and launched the product in the United States, expanding the global pharmaceutical company’s portfolio of generic injectable medicines. The newly launched Sugammadex Injection is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials. Lupin’s product is bioequivalent to Bridion® Injection from Merck Sharp & Dohme LLC and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged two years and older undergoing surgery. The FDA approval followed review of Lupin’s ANDA and enables the company to commercially introduce its generic version of the injectable medicine into the U.S. market.
FDA ANDA Approval Expands Lupin’s U.S. Generic Portfolio
The FDA approval and immediate U.S. launch of Sugammadex Injection represent another regulatory and commercialization milestone for Lupin as the company continues to strengthen its presence in the American pharmaceutical market. Through the ANDA pathway, generic drug manufacturers must demonstrate that their proposed product meets applicable regulatory requirements, including demonstrating bioequivalence to the reference listed drug. Lupin stated that its Sugammadex Injection is bioequivalent to Bridion Injection, providing a generic option in two single-dose vial presentations. The availability of both 200 mg/2 mL and 500 mg/5 mL formulations at a concentration of 100 mg/mL provides dosing presentations for use in appropriate surgical settings. The launch also reflects Lupin’s broader strategy of supplying pharmaceutical products across major therapeutic markets while expanding its presence in complex and differentiated generic medicines.
Sugammadex Reverses Neuromuscular Blockade During Surgery
Sugammadex Injection is indicated for reversal of neuromuscular blockade caused by rocuronium bromide and vecuronium bromide, medications used to produce muscle relaxation during surgical procedures. Lupin’s FDA-approved generic can be used in adult and pediatric patients aged two years and older undergoing surgery, according to the company’s announcement. Reversal of neuromuscular blockade is an important component of perioperative and anesthesia management because patients need to recover appropriate neuromuscular function following administration of neuromuscular blocking agents. The U.S. launch therefore adds another generic injectable treatment option for healthcare professionals managing patients following procedures involving rocuronium or vecuronium. The regulatory milestone is particularly relevant to Lupin’s U.S. operations because injectable medicines require rigorous development, manufacturing and quality standards before they can enter the market. FDA approval confirms that Lupin’s ANDA met the regulatory requirements necessary for commercialization of the generic product in the United States.
Advertisement
Lupin Strengthens Global Pharmaceutical and U.S. Presence
The Sugammadex launch adds to Lupin’s broad pharmaceutical portfolio spanning branded formulations, generic medicines, complex generics, biotechnology products and active pharmaceutical ingredients. Headquartered in Mumbai, India, the company distributes products across more than 100 markets worldwide and maintains significant positions in both India and the United States. Lupin’s therapeutic presence includes respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system and women’s health medicines. The company operates 15 manufacturing facilities and seven research centers globally, supported by more than 26,000 employees. Its broader healthcare operations also include Lupin Diagnostics, Lupin Digital Health and Lupin Manufacturing Solutions. The FDA approval and U.S. commercial launch of Sugammadex Injection reinforce Lupin’s continued focus on bringing generic pharmaceutical alternatives to major global markets while leveraging its research, manufacturing and regulatory capabilities. For the U.S. market, the launch provides another FDA-approved generic alternative to an established branded injectable therapy used in surgical care. The development also highlights continued activity within the U.S. generic injectable sector, where regulatory approvals can expand product availability and competition. With commercial distribution now underway following FDA approval, Sugammadex Injection becomes the latest addition to Lupin’s growing U.S. pharmaceutical portfolio and strengthens the company’s presence in perioperative and hospital-based medicine.
Source: Lupin press release
